Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 19/20 | 0.85 |
| ▸ | KDR | P35968 | 13/20 | 0.78 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11925847 | 0.92 | FGFR3 (1.00) | FGFR3KDR | |
| SCHEMBL11925888 | 0.89 | FGFR3 (1.00) | FGFR3KDR | |
| SCHEMBL11929191 | 0.88 | FGFR3 (1.00) | FGFR3KDR | |
| SCHEMBL11925907 | 0.88 | FGFR3 (1.00) | FGFR3KDR | |
| SCHEMBL601349 | 0.87 | FGFR3 (0.75) | FGFR3KDRFGFR4 | |
| SCHEMBL11925885 | 0.86 | FGFR3 (0.79) | FGFR3KDR | |
| SCHEMBL11925902 | 0.86 | FGFR3 (1.00) | FGFR3KDR | |
| SCHEMBL11929349 | 0.86 | FGFR3 (1.00) | FGFR3KDR | |
| SCHEMBL3325671 | 0.86 | FGFR3 (0.72) | FGFR3KDRFGFR4 | |
| SCHEMBL601043 | 0.86 | FGFR3 (0.77) | FGFR3KDRFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419428-B1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY | ASTEX THERAPEUTICS LTD (GB) | 2015-05-13 | — | — | EP | disclosed |
| US-8722687-B2 | Imidazo [1,2-A]pyridine derivatives as FGFR kinase inhibitors for use in therapy | ASTEX THERAPEUTICS LTD (GB) | 2014-05-13 | — | — | US | disclosed |
| US-8722687-B2 | Imidazo [1,2-A]pyridine derivatives as FGFR kinase inhibitors for use in therapy | ASTEX THERAPEUTICS LTD (GB) | 2014-05-13 | — | — | US | disclosed |
| EP-2419428-A1 | IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY | Astex Therapeutics Ltd. (GB) | 2012-02-22 | — | — | EP | disclosed |
| US-20120041000-A1 | IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120041000-A1 | IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| WO-2010119285-A1 | IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041000-A1 | IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY | FGFR1, FGFR3, FGFR2 | FGFR3 2/4885KDR 41/4885FGFR4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.